Division of Cardiothoracic Transplantation and Circulatory Support, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
Tex Heart Inst J. 2023 Aug 22;50(4). doi: 10.14503/THIJ-23-8100.
Postoperative respiratory failure is a major complication that affects up to 10% of patients who undergo cardiac surgery and has a high in-hospital mortality rate. Few studies have investigated whether patients who require tracheostomy for postoperative respiratory failure after continuous-flow left ventricular assist device (CF-LVAD) implantation have worse survival outcomes than patients who do not.
To identify risk factors for respiratory failure necessitating tracheostomy in CF-LVAD recipients and to compare survival outcomes between those who did and did not require tracheostomy.
Consecutive patients who underwent primary CF-LVAD placement at a single institution between August 1, 2002, and December 31, 2019, were retrospectively reviewed. Propensity score matching accounted for baseline differences between the tracheostomy and nontracheostomy groups. Multivariate logistic regression was used to identify tracheostomy risk factors and 90-day survival; Kaplan-Meier analysis was used to assess midterm survival.
During the study period, 664 patients received a CF-LVAD; 106 (16.0%) underwent tracheostomy for respiratory failure. Propensity score matching produced 103 matched tracheostomy-nontracheostomy pairs. Patients who underwent tracheostomy were older (mean [SD] age, 57.9 [12.3] vs 54.6 [13.9] years; P = .02) and more likely to need preoperative mechanical circulatory support (61.3% vs 47.8%; P = .01) and preoperative intubation (27.4% vs 8.8%; P < .001); serum creatinine was higher in the tracheostomy group (mean [SD], 1.7 [1.0] vs 1.4 [0.6] mg/dL; P < .001), correlating with tracheostomy need (odds ratio, 1.76; 95% CI, 1.21-2.56; P = .003). Both before and after propensity matching, 30-day, 60-day, 90-day, and 1-year survival were worse in patients who underwent tracheostomy. Median follow-up was 0.8 years (range, 0.0-11.2 years). Three-year Kaplan-Meier survival was significantly worse for the tracheostomy group before (22.0% vs 61.0%; P < .001) and after (22.4% vs 48.3%; P < .001) matching.
Given the substantially increased probability of death in patients who develop respiratory failure and need tracheostomy, those at high risk for respiratory failure should be carefully considered for CF-LVAD implantation. Comprehensive management to decrease respiratory failure before and after surgery is critical.
术后呼吸衰竭是影响高达 10%接受心脏手术患者的主要并发症,且院内死亡率较高。很少有研究调查因持续血流左心室辅助装置(CF-LVAD)植入术后呼吸衰竭而需要气管切开的患者的生存结果是否比不需要气管切开的患者差。
确定 CF-LVAD 接受者发生需要气管切开的呼吸衰竭的危险因素,并比较需要和不需要气管切开的患者的生存结果。
回顾性分析 2002 年 8 月 1 日至 2019 年 12 月 31 日在一家机构接受初次 CF-LVAD 植入的连续患者。倾向评分匹配用于校正气管切开组和非气管切开组之间的基线差异。多变量逻辑回归用于确定气管切开的危险因素和 90 天生存率;Kaplan-Meier 分析用于评估中期生存率。
在研究期间,664 例患者接受了 CF-LVAD;106 例(16.0%)因呼吸衰竭行气管切开。进行倾向评分匹配后产生了 103 对匹配的气管切开术与非气管切开术的配对。行气管切开术的患者年龄较大(平均[标准差]年龄,57.9[12.3]岁 vs 54.6[13.9]岁;P=0.02),更可能需要术前机械循环支持(61.3% vs 47.8%;P=0.01)和术前插管(27.4% vs 8.8%;P<.001);气管切开组的血清肌酐更高(平均值[标准差],1.7[1.0]mg/dL vs 1.4[0.6]mg/dL;P<.001),与气管切开术的需要相关(比值比,1.76;95%置信区间,1.21-2.56;P=0.003)。在进行倾向匹配之前和之后,行气管切开术的患者的 30 天、60 天、90 天和 1 年生存率均较差。中位随访时间为 0.8 年(范围,0.0-11.2 年)。在匹配之前(22.0% vs 61.0%;P<.001)和之后(22.4% vs 48.3%;P<.001),气管切开组的 3 年 Kaplan-Meier 生存率均显著降低。
鉴于发生呼吸衰竭和需要气管切开的患者死亡的概率大大增加,因此应仔细考虑对有发生呼吸衰竭高风险的患者进行 CF-LVAD 植入。术前和术后全面减少呼吸衰竭的管理至关重要。